Recent Advances in the Development of Selective CB2 Agonists as Promising Anti-Inflammatory Agents

Title:Recent Advances in the Development of Selective CB2 Agonists as Promising Anti-Inflammatory Agents

Volume: 19 Issue: 21

Author(s): N. Leleu-Chavain, M. Body-Malapel, J. Spencer, P. Chavatte, P. Desreumaux and R. Millet

Affiliation:

Keywords: cannabinoids, CB2 receptors, CB2 agonists, inflammation, anti-inflammatory agents, central nervous system inflammation, chronic inflammatory diseases, IBD, Crohn’s disease, ulcerative colitis, ischemia/reperfusion injury, aminoalkylindoles, tricyclic pyrazoles, morpholines, quinolones

Abstract: The high distribution of CB2 receptors in immune cells suggests their important role in the control of inflammation. Growing evidence offers this receptor as an attractive therapeutic target: CB2 selective agonists are able to modulate inflammation without triggering psychotropic effects. This review will summarize the literature on the implication of CB2 in inflammation and CB2 selective agonists with anti-inflammatory activity.

Cite this article as:

Leleu-Chavain N., Body-Malapel M., Spencer J., Chavatte P., Desreumaux P. and Millet R., Recent Advances in the Development of Selective CB2 Agonists as Promising Anti-Inflammatory Agents, Current Medicinal Chemistry 2012; 19 (21) . https://dx.doi.org/10.2174/092986712801323207